AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation of its Scientific Advisory Board (SAB), which is comprised of industry experts in autoimmune and inflammatory disease drug development. The SAB will work closely with the AbolerIS team to advance its lead program, ABO21009, a humanized anti-CD45RC monoclonal antibody, through Phase 1 for rheumatoid arthritis (RA). Pending clinical proof-of-concept in RA, the Company intends to broaden its development into other autoimmune diseases. Durable, long-term remission remains elusive in many autoimmune diseases such as RA. The SAB will also assist the AbolerIS management with the planned development of additional indications for ABO21009 and the expansion and subsequent development of the Company’s portfolio.
The members of our Scientific Advisory Board combine deep preclinical, translational and clinical expertise in a broad range of autoimmune diseases.
Ronald Van Brempt, MD, Chief Medical Officer of AbolerIS, commented: “We are privileged to work with Dirk, Mary, Georg, Rene, Michel, Edouard, and Ignacio, to bring a novel therapy like ABO21009 to patients suffering from the debilitating effects of autoimmune disease. These recognized leaders bring a great understanding of inflammatory and autoimmune diseases, as well as deep expertise in advancing scientific breakthroughs towards the clinic. We look forward to their contributions as we advance ABO21009 in the clinic for RA and additional indications like Sjögren`s Disease, Graft-versus-Host Disease, Inflammatory Bowel Disease, and Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy as we continue to grow our company.”
Members of the AbolerIS Scientific Advisory Board are listed below. Complete biographies are available on the AbolerIS website.
Dirk Elewaut, MD, PhD, Chairman of the Scientific Advisory Board:
Full Professor of Rheumatology and Immunology and Chair of the Department of Rheumatology and Immunology at Ghent University Hospital, Ghent, Belgium
VIB Group leader, VIB-UGent Center for Inflammation Research, Ghent, Belgium
“I have dedicated my career to advancing research in immunology and inflammatory disease, and the potential of ABO21009 is very promising. I am honored to lead the world-class leaders on the SAB with the goal to advance AbolerIS’ research toward patients in need,” commented Dr. Elewaut.
Mary Crow, MD, PhD
Physician-in-Chief Emeritus at Hospital for Special Surgery, Professor of Medicine at Weill Cornell Medical College, and Professor of Immunology in its Graduate School of Medical Sciences, New York, USA
Senior Scientist, Co-Director of the Mary Kirkland Center for Lupus Research, and Director of the Autoimmunity and Inflammation Program at Hospital for Special Surgery’s Research Institute (holder of the Benjamin M. Rosen Chair in Immunology and Inflammation Research), New York, USA
Georg Schett, MD, PhD
Vice President Research, Chair of Internal Medicine III – Rheumatology and Immunology, Uniklinikum Erlangen – Friedrich Alexander University, Erlangen-Nurnberg, Germany
Rene Toes, PhD
Full Professor of Experimental Rheumatology, Leiden University Medical Center (LUMC), Leiden, the Netherlands
Head of the Laboratory of Dept. of Rheumatology, LUMC, Leiden, the Netherlands
Michel Goldman, MD, PhD
Founder and the President of the I³h Institute and Professor of Immunology and Pharmacotherapy at the Université libre de Bruxelles (ULB)
Executive Director Emeritus of the Innovative Medicines Initiative (IMI) from 2009 to 2014
Head Emeritus of the Department of Immunology at Erasme Hospital and Director Emeritus of the Institute for Medical Immunology (ULB)
Edouard Louis, MD, PhD
Professor of Gastroenterology and Head of the Gastroenterology department at Liège University hospital. Liege, Belgium
Dean of the faculty of Medicine at Liège University, Liege, Belgium
Ignacio Anegon, MD, PhD
Director of Research (DRE) at INSERM-CRTI
Director Transgenesis Rat ImmunoPhenomic facility, Co-Founder of AbolerIS Pharma
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
